The European Union's health regulator said on Wednesday it was reviewing Valneva's chikungunya vaccine after reports of ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) has started a review of Valneva’s single-dose live attenuated ...

Recommendations for the use of chikungunya vaccine were recently discussed at a meeting of the Advisory Committee on Immunization Practices.

French health authorities have suspended the use of Valneva’s chikungunya vaccine Ixchiq in adults aged 65 and older after ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Bavarian Nordic’s Vimkunya (recombinant, adsorbed ...

Shares in Valneva plunged after the company said France's health authorities suspended the use of its chikungunya vaccine, Ixchiq, for people aged 65 and older, raising concerns about the vaccine's ...

Shares of French speciality vaccines developer Valneva (Nasdaq: VAL) were down 8.4% at 2.89 euros by early afternoon, after ...

The country is considered the epicenter of the disease in the Americas, with epidemics reported over the years.

Valneva has been responding to the French government’s call for vaccine supply of IXCHIQ® in La Reunion1 as the island is going through a major chikungunya outbreak with ~ 40,000 confirmed ...

Valneva will provide a live webcast of its first quarter 2025 results conference call beginning at 3 p.m. CEST/9 a.m. EDT today. This webcast will also be available on the Company’s website. Please ...